Patents Examined by Sudhakar Katakam
  • Patent number: 12180136
    Abstract: A method is provided for collecting a compound of formula (III) (in which R31 is a monovalent to trivalent organic group and n31 is an integer of 1 to 3) from a liquid phase component that is formed as a by-product in a method for producing a compound of general formula (I) (in which R11 is a monovalent to trivalent organic group and n11 is an integer of 1 to 3), wherein the collection method contains steps (1) to (3) or steps (A) and (B), and step (4). Step (1): a step for reacting the liquid phase component with at least one active hydrogen-containing compound in a reactor. Step (2): a step for returning a condensed liquid obtained by cooling gas phase components in the reactor to the reactor. Step (3): a step for discharging gas phase components that are not condensed in the step (2) to the outside of the reactor. Step (A): a step for mixing the liquid phase component, water, and a compound of general formula (III). Step (B): a step for reacting the liquid phase component with water inside the reactor.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: December 31, 2024
    Assignee: Asahi Kasel Kabushiki Kaisha
    Inventors: Nobuhisa Miyake, Masaaki Shinohata, Yusuke Sakurai, Yusuke Ishii, Takeharu Sasaki
  • Patent number: 12180265
    Abstract: A pharmaceutical composition comprises (a) a peptide of 8 to 20 amino acids comprising at least one citrulline residue and 13, 14 or 15 consecutive amino acids residues with a sequence present in SEQ ID NO 22 or a complex of said peptide and a human recombinant MHC class II protein, and (b) an immunologic adjuvant.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: December 31, 2024
    Assignee: Curara AB
    Inventors: Lars Klareskog, Vivianne Malmstström
  • Patent number: 12180144
    Abstract: An embodiment relates to a diamine compound, a polymer including a structural unit derived therefrom, a composition for forming a polyimide film including the polymer, and a polyimide film prepared by using the composition. Specifically, the diamine compound according to an embodiment may be very usefully used as a monomer for preparing a polyimide film that is colorless and has an improved mechanical strength.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: December 31, 2024
    Assignees: SK Innovation Co., Ltd., SK ie technology Co., Ltd.
    Inventors: Hyo Shin Kwak, Hye Ri Kim, Jin Hyung Park, Hyun Kyu Cho
  • Patent number: 12180249
    Abstract: This disclosure relates to compositions and methods for selective labeling of N-alkyl lysine, N-alkyl adenosine, proline, N-alkyl cytosine, peptides, nucleic acids, or aliphatic or aromatic secondary amines. In certain embodiments, this disclosure relates to methods of forming triazene labeled compounds comprising contacting a compound containing a secondary amine group with a compound comprising an aromatic group with a diazonium para substituted with an electron rich group under conditions such that a triazene labeled compound is formed at the secondary amine group.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: December 31, 2024
    Assignee: Emory University
    Inventors: Monika Raj, Ogonna Nwajiobi
  • Patent number: 12171836
    Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: December 24, 2024
    Assignee: UNIVERSITY OF MIYAZAKI
    Inventors: Kazuo Kitamura, Motoo Yamasaki
  • Patent number: 12172946
    Abstract: A structure of the compound containing a diphenylmethane structure of the present invention is represented by General Formula (1). The compound containing a diphenylmethane structure of the present invention contains a hydroxyl group, an amino group, a substituted amino group, and an active group, and can be used as an amino acid or peptide C-terminal protection reagent. A peptide synthesis reaction using this protection carrier has a fast reaction speed and a high reagent utilization rate in a suitable solvent system; post-treatment is carried out by means of simple liquid-liquid extraction separation, i.e. effective purification can be carried out, and finally, a product with a high purity can be obtained; and during a synthesis process, the change in solubility is small and an operation process has a strong universality, and therefore, the present method can be developed into a universal production method.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: December 24, 2024
    Assignee: GUANGZHOU TROJAN PHARMATEC LTD.
    Inventors: Weizhou Liang, Qingquan Zheng, Qi Tang
  • Patent number: 12163168
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: December 10, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Everett Stone, Wei-Cheng Lu, Christos Karamitros
  • Patent number: 12162842
    Abstract: A process for the conversion of glycolaldehyde with an aminating agent in the presence of hydrogen and of a catalyst in a glycolaldehyde conversion reactor, wherein one or more organic carboxylic acids are fed into the glycolaldehyde conversion reactor.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: December 10, 2024
    Assignee: BASF SE
    Inventors: Martin Ernst, Tatjana Huber, Johann-Peter Melder, Stephanie Jaegli, Thomas Krug
  • Patent number: 12162829
    Abstract: Catalysts and catalytic processes for the synthesis of acrylic acid and other ?,?-unsaturated carboxylic acids and their salts, which are carried out in a diluent or in the absence of a diluent. In an aspect, ethylene and CO2 can be contacted with a Group 8-11 transition metal precursor compound or a Group 8-11 transition metal metalalactone compound in the presence of a metal-treated chemically-modified solid oxide (MT-CMSO) or a metal-treated solid oxide (MT-SO), to form a metal acrylate. As the catalytic activity wanes in either the presence or absence of a diluent, pressure cycling—that is, pressurizing the reaction system with CO2 and an olefin such as ethylene for a time period, releasing the pressure, then re-pressurizing with CO2 and ethylene—can rejuvenate the catalyst and restore its declining catalytic activity.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: December 10, 2024
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Pasquale Iacono, Jamie N. Sutherland, Carlton E. Ash, Anand Ramanathan
  • Patent number: 12162914
    Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: December 10, 2024
    Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
  • Patent number: 12157870
    Abstract: An agent, such as a detergent or cleaning agent, may include a polyesterase. A method for cleaning textiles may include applying the agent to a textile for removing soiling. The polyesterase may also help to reduce pilling effects in the agent.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: December 3, 2024
    Assignee: HENKEL AG & CO. KGAA
    Inventors: Christian Degering, Jasmin Eidner, Thomas Haarmann, Shohana Islam, Felix Jakob, Patrick Lorenz, Nina Mussmann, Kristin Ruebsam, Ulrich Schwaneberg, Ruth Schwerdtfeger, Lina Apitius, Ren Wei, Susanne Wieland, Wolfgang Zimmermann
  • Patent number: 12157777
    Abstract: The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 3, 2024
    Assignee: AXELIA ONCOLOGY PTY LTD
    Inventors: David Jackson, Ian Holmes, Weiguang Zeng, Christophe Demaison
  • Patent number: 12157715
    Abstract: A method for producing a highly polymerizable N-vinyl carboxylic acid amide monomer includes (A) melting a crude N-vinyl carboxylic acid amide monomer including 50 to 88 mass % of an N-vinyl carboxylic acid amide monomer by heating, followed by cooling for precipitation, and subjecting precipitated N-vinyl carboxylic acid amide monomer crystals to solid-liquid separation (step (A)), and (B) further dissolving the N-vinyl carboxylic acid amide monomer crystals separated in step (A) in a mixed solvent of 1,2-dimethoxyethane and an aliphatic hydrocarbon having 6 to 7 carbon atoms, then performing crystallization, performing solid-liquid separation, and recovering an N-vinyl carboxylic acid amide monomer purified product (step (B)), wherein a mass ratio of 1,2-dimethoxyethane/N-vinyl carboxylic acid amide monomer crystal in step (B) is 0.01 to 0.5, and a mass ratio of aliphatic hydrocarbon having 6 to 7 carbon atoms/N-vinyl carboxylic acid amide monomer crystal in step (B) is 0.5 to 3.0.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: December 3, 2024
    Assignee: Resonac Corporation
    Inventors: Takamitsu Kobayashi, Naoyuki Tanaka
  • Patent number: 12152000
    Abstract: This invention relates to a novel process for making dihydrotetrabenazines, and in particular (+)-?-dihydrotetrabenazine, novel synthetic intermediates for use in the process and processes for making the intermediates.
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: November 26, 2024
    Assignee: ADEPTIO PHARMACEUTICALS LIMITED
    Inventors: Kishor Bapu Gavhane, Nitin Punjaji Lad, Ramakrishna Guduru, Sunit Ramesh Kulkarni
  • Patent number: 12152063
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 26, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Patent number: 12152054
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Hui F. Liu, Brian David Kelley, Deanna E. Myers, Beth McCooey, Krista Marie Petty
  • Patent number: 12151997
    Abstract: The invention relates to a method for preparing a suspension of a hydrochloride of an organic amine, comprising the following steps of (i) initially charging at least one organic solvent in a reaction vessel to form a liquid level, (ii) adding hydrogen chloride, (iii) adding the organic amine, wherein the organic amine is added below the liquid level present in the reaction vessel and steps (ii) and (iii) are at least partly carried out simultaneously. Furthermore, the present invention also relates to a method wherein the suspension obtained after step (iii) is reacted in a step (iv) with phosgene to obtain the organic isocyanate corresponding to the organic amine used, to the corresponding organic isocyanate and to the use of the organic isocyanate for producing polyisocyanates.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: November 26, 2024
    Assignee: Covestro Intellectual Property GmbH & Co. KG
    Inventors: Michael Merkel, Tim Loddenkemper, Frank Gerhartz, Stefan Hirschfeld
  • Patent number: 12138293
    Abstract: This disclosure provides formulations suitable for topical ophthalmic delivery of peptide therapeutics. The disclosure also provides compositions and methods for treating ocular injury. The compositions and formulations may include therapeutically active alpha connexin peptides.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: November 12, 2024
    Assignee: XEQUEL BIO, INC.
    Inventors: Gautam Ghatnekar, Christina Grek
  • Patent number: 12138292
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: June 13, 2022
    Date of Patent: November 12, 2024
    Assignee: Centauri Therapeutics Limited (GB/GB)
    Inventors: Michael Westby, Melanie Glossop, Christine Watson
  • Patent number: 12139518
    Abstract: The present application relates to compositions and methods comprising polypeptides derived from MFG-E8 for treating and preventing fibrosis and other diseases.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: November 12, 2024
    Assignee: Nexel Co., Ltd.
    Inventors: Choongseong Han, Dong-Hun Woo, Xiong Jin, Jaehun Lee, Geun Ho An, Tack Jin Yoo, Jinwoo Chung